Olmesafe-AM 5 mg+40 mg (Tablet)

Indications

• Treatment of hypertension alone or with other antihypertensive agents
• Lowering blood pressure

Pharmacology

• Amlodipine as a dihydropyridine calcium channel blocker
• Olmesartan Medoxomil as an angiotensin II receptor antagonist

Dosage & Administration

• Initial therapy with 5/20 mg once daily
• Titration up to maximum of 10/40 mg once daily

Interaction

• Attenuation of antihypertensive effect by NSAIDs
• Close monitoring of blood pressure, renal function, and electrolytes

Contraindications

• Co-administration with Aliskiren in patients with diabetes

Side Effects

• Peripheral edema
• Headache
• Flushing
• Dizziness
• Sprue-like enteropathy

Pregnancy & Lactation

• Pregnancy Category D
• Discontinue in 2nd and 3rd trimester
• Unknown excretion in human milk
• Adverse effects on nursing infant

Precautions & Warnings

• Caution in volume- or salt-depleted patients
• Risk in patients with severe aortic stenosis
• Risk in patients with severe obstructive coronary artery disease

Use in Special Populations

• Safety and effectiveness not established in pediatric patients
• No overall differences in safety or effectiveness in subjects aged 65 years or older
• No studies in patients with renal impairment
• Initial therapy not recommended in hepatically impaired patients

Overdose Effects

• No information on overdose in humans

Therapeutic Class

• Combined antihypertensive preparations

Storage Conditions

• Do not store above 30°C
• Keep away from light and out of the reach of children

Related Brands

• Abecab 5 mg+20 mg (Tablet) - aci-limited
• Abecab 5 mg+40 mg (Tablet) - aci-limited
• Bizoran 5 mg+20 mg (Tablet) - beximco-pharmaceuticals-ltd
• Camlosart 5 mg+20 mg (Tablet) - square-pharmaceuticals-plc
• Camlosart 5 mg+40 mg (Tablet) - square-pharmaceuticals-plc